Document Detail

Virus-like particles from rabbit hemorrhagic disease virus can induce an anti-tumor response.
MedLine Citation:
PMID:  18706958     Owner:  NLM     Status:  MEDLINE    
Recombinant virus-like particles (VLP) expressing heterologous tumor antigens have recently been investigated for use as vaccines. We have chemically conjugated ovalbumin (OVA) or OVA-derived CD4 (OTII) and CD8 (OTI) epitopes, to rabbit hemorrhagic disease virus (RHDV) VLP. VLP conjugated with OVA were able to cross-prime CD8+ cells from OT1 mice transgenic for the OVA T cell receptor. VLP.OTI was able to induce higher antigen-specific cytotoxicity in vivo than VLP mixed with either the protein or the peptide. Furthermore we have shown that the growth of the aggressive B16.OVA melanoma in mice was significantly delayed in those animals that had been vaccinated with VLP.OVA or with VLP coupled with both OTI and OTII peptides prior to the introduction of the tumor. Neither VLP.OTI nor VLP.OTII alone were capable of inhibiting tumor growth. This work suggests that RHDV VLP offer a versatile scaffold for multiple vaccine epitopes, enabling cross-presentation of the antigen to elicit potent cell-mediated and anti-tumor responses.
Matthew Peacey; Sarah Wilson; Rachel Perret; Franca Ronchese; Vernon K Ward; Vivienne Young; Sarah L Young; Margaret A Baird
Related Documents :
22181328 - Radiosurgery of spinal meningiomas and schwannomas.
24778318 - Establishment of tumor-associated immunity requires interaction of heat shock proteins ...
2302738 - Clonal analysis in the ultrastructure of cell-to-cell interaction between a human gliom...
18523278 - Ctls directed against her2 specifically cross-react with her3 and her4.
12798698 - Changes in the topological expression of markers of differentiation and apoptosis in de...
8995508 - Effect of angiotensin ii on immunotoxin uptake in tumor and normal tissue.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-08-14
Journal Detail:
Title:  Vaccine     Volume:  26     ISSN:  0264-410X     ISO Abbreviation:  Vaccine     Publication Date:  2008 Oct 
Date Detail:
Created Date:  2008-09-15     Completed Date:  2008-11-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8406899     Medline TA:  Vaccine     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  5334-7     Citation Subset:  IM    
Department of Microbiology and Immunology, School of Medical Sciences, University of Otago, 720 Cumberland Street, Dunedin, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antigen Presentation / immunology
Antigens, CD4 / immunology
Antigens, CD8 / immunology
Antigens, Neoplasm / immunology
CD8-Positive T-Lymphocytes / immunology*
Cancer Vaccines / immunology,  therapeutic use*
Epitopes, T-Lymphocyte / immunology,  therapeutic use
Hemorrhagic Disease Virus, Rabbit / immunology*
Melanoma, Experimental / immunology,  therapy
Mice, Inbred C57BL
Mice, Transgenic
Ovalbumin / immunology,  therapeutic use*
Reg. No./Substance:
0/Antigens, CD4; 0/Antigens, CD8; 0/Antigens, Neoplasm; 0/Cancer Vaccines; 0/Epitopes, T-Lymphocyte; 9006-59-1/Ovalbumin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The cost-effectiveness of using hepatitis A/B combined vaccine versus hepatitis B vaccine alone for ...
Next Document:  Development and immunogenicity of recombinant Mycoplasma gallisepticum vaccine strain ts-11 expressi...